Literature DB >> 10225879

Replication of Toxoplasma gondii, but not Trypanosoma cruzi, is regulated in human fibroblasts activated with gamma interferon: requirement of a functional JAK/STAT pathway.

I P Cerávolo1, A C Chaves, C A Bonjardim, D Sibley, A J Romanha, R T Gazzinelli.   

Abstract

To study the role of tryptophan degradation by indoleamine 2, 3-dioxygenase (INDO) in the control of Trypanosoma cruzi or Toxoplasma gondii replication, we used human fibroblasts and a fibrosarcoma cell line (2C4). The cells were cultured in the presence or absence of recombinant gamma interferon (rIFN-gamma) and/or recombinant tumor necrosis factor alpha (rTNF-alpha) for 24 h and were then infected with either T. cruzi or T. gondii. Intracellular parasite replication was evaluated 24 or 48 h after infection. Treatment with rIFN-gamma and/or rTNF-alpha had no inhibitory effect on T. cruzi replication. In contrast, 54, 73, or 30% inhibition of T. gondii replication was observed in the cells treated with rIFN-gamma alone, rIFN-gamma plus rTNF-alpha, or TNF-alpha alone, respectively. The replication of T. gondii tachyzoites in cytokine-activated cells was restored by the addition of extra tryptophan to the culture medium. Similarly, T. gondii tachyzoites transfected with bacterial tryptophan synthase were not sensitive to the microbiostatic effect of rIFN-gamma. We also investigated the basis of the cytokine effect on parasite replication by using the three mutant cell lines B3, B9, and B10 derived from 2C4 and expressing defective STAT1alpha (signal transducer and activator of transcription), JAK2 (Janus family of cytoplasmic tyrosine kinases), or JAK1, respectively, three important elements of a signaling pathway triggered by rIFN-gamma. We found that rTNF-alpha was able to induce low levels expression of INDO mRNA in the parental cell line, as well as the cell line lacking functional JAK2. In contrast to the parental cell line (2C4), rIFN-gamma was not able to induce the expression of INDO mRNA or microbiostatic activity in any of the mutant cell lines. These findings indicate the essential requirement of the JAK/STAT pathway for the induction of high levels of INDO mRNA, tryptophan degradation, and the anti-Toxoplasma activity inside human nonprofessional phagocytic cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225879      PMCID: PMC115962     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

1.  Intracellular murine IFN-gamma mediates virus resistance, expression of oligoadenylate synthetase, and activation of STAT transcription factors.

Authors:  A Will; U Hemmann; F Horn; M Röllinghoff; A Gessner
Journal:  J Immunol       Date:  1996-11-15       Impact factor: 5.422

2.  Effect of interferon on the infectivity of Trypanosoma cruzi in cultured HeLa cells.

Authors:  A Osuna; G Ortega; F Gamarro; S Castanys; L M Ruiz-Perez
Journal:  Int J Parasitol       Date:  1985-04       Impact factor: 3.981

3.  Beta-interferon inhibits cell infection by Trypanosoma cruzi.

Authors:  F Kierszenbaum; G Sonnenfeld
Journal:  J Immunol       Date:  1984-02       Impact factor: 5.422

4.  Human mononuclear phagocyte antiprotozoal mechanisms: oxygen-dependent vs oxygen-independent activity against intracellular Toxoplasma gondii.

Authors:  H W Murray; B Y Rubin; S M Carriero; A M Harris; E A Jaffee
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

5.  Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan.

Authors:  E R Pfefferkorn
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

6.  Intraspecific variation in Trypanosoma cruzi: effect of temperature on the intracellular differentiation in tissue culture.

Authors:  M S Bertelli; R R Golgher; Z Brener
Journal:  J Parasitol       Date:  1977-06       Impact factor: 1.276

7.  Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine.

Authors:  H W Murray; B Y Rubin; C D Rothermel
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

8.  Effects of leukotriene C4 on macrophage association with and intracellular fate of Trypanosoma cruzi.

Authors:  J J Wirth; F Kierszenbaum
Journal:  Mol Biochem Parasitol       Date:  1985-04       Impact factor: 1.759

9.  Synergistic protection by specific antibodies and interferon against infection by Trypanosoma cruzi in vitro.

Authors:  F Plata; J Wietzerbin; F G Pons; E Falcoff; H Eisen
Journal:  Eur J Immunol       Date:  1984-10       Impact factor: 5.532

10.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.

Authors:  C F Nathan; H W Murray; M E Wiebe; B Y Rubin
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  18 in total

1.  Interaction of natural killer cells with Trypanosoma cruzi-infected fibroblasts.

Authors:  T Lieke; C Steeg; S E B Graefe; B Fleischer; T Jacobs
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

Review 2.  Toxoplasma Effectors Targeting Host Signaling and Transcription.

Authors:  Mohamed-Ali Hakimi; Philipp Olias; L David Sibley
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

3.  Expression of indoleamine 2,3-dioxygenase, tryptophan degradation, and kynurenine formation during in vivo infection with Toxoplasma gondii: induction by endogenous gamma interferon and requirement of interferon regulatory factor 1.

Authors:  Neide M Silva; Cibele V Rodrigues; Marcelo M Santoro; Luiz F L Reis; Jacqueline I Alvarez-Leite; Ricardo T Gazzinelli
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

4.  The function of gamma interferon-inducible GTP-binding protein IGTP in host resistance to Toxoplasma gondii is Stat1 dependent and requires expression in both hematopoietic and nonhematopoietic cellular compartments.

Authors:  Carmen M Collazo; George S Yap; Sara Hieny; Patricia Caspar; Carl G Feng; Gregory A Taylor; Alan Sher
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

Review 5.  IFN-induced cell-autonomous immune mechanisms in the control of intracellular protozoa.

Authors:  Sini Skariah; Ali A Sultan; Dana G Mordue
Journal:  Parasitol Res       Date:  2022-04-18       Impact factor: 2.383

6.  Monocytes from patients with indeterminate and cardiac forms of Chagas' disease display distinct phenotypic and functional characteristics associated with morbidity.

Authors:  Paulo E A Souza; Manoel O C Rocha; Etel Rocha-Vieira; Cristiane A S Menezes; Andréa C L Chaves; Kenneth J Gollob; Walderez O Dutra
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

7.  Toxoplasma gondii infection and risk of attention-deficit hyperactivity disorder: a systematic review and meta-analysis.

Authors:  Tooran Nayeri; Shahabeddin Sarvi; Mahmood Moosazadeh; Zahra Hosseininejad; Afsaneh Amouei; Ahmad Daryani
Journal:  Pathog Glob Health       Date:  2020-03-18       Impact factor: 2.894

8.  Interferon-gamma promotes infection of astrocytes by Trypanosoma cruzi.

Authors:  Rafael Rodrigues Silva; Rafael M Mariante; Andrea Alice Silva; Ana Luiza Barbosa dos Santos; Ester Roffê; Helton Santiago; Ricardo Tostes Gazzinelli; Joseli Lannes-Vieira
Journal:  PLoS One       Date:  2015-02-19       Impact factor: 3.240

9.  Heme oxygenase-1 activity is involved in the control of Toxoplasma gondii infection in the lung of BALB/c and C57BL/6 and in the small intestine of C57BL/6 mice.

Authors:  Ester C B Araujo; Bellisa F Barbosa; Loyane B Coutinho; Paulo V C Barenco; Luciana A Sousa; Cristiane M Milanezi; Giuliano Bonfá; Wander R Pavanelli; João S Silva; Eloisa A V Ferro; Deise A O Silva; Jair P Cunha-Junior; Neide M Silva
Journal:  Vet Res       Date:  2013-10-02       Impact factor: 3.683

10.  Intravenous administration of LPS activates the kynurenine pathway in healthy male human subjects: a prospective placebo-controlled cross-over trial.

Authors:  Vincent Millischer; Matthias Heinzl; Anthi Faka; Michael Resl; Ada Trepci; Carmen Klammer; Margot Egger; Benjamin Dieplinger; Martin Clodi; Lilly Schwieler
Journal:  J Neuroinflammation       Date:  2021-07-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.